A randomized, double-blind, placebo-controlled, 3-way cross-over study to evaluate the effects of APD125 in patients with chronic primary insomnia

Trial Profile

A randomized, double-blind, placebo-controlled, 3-way cross-over study to evaluate the effects of APD125 in patients with chronic primary insomnia

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Jun 2016

At a glance

  • Drugs Nelotanserin (Primary)
  • Indications Insomnia
  • Focus Therapeutic Use
  • Sponsors Arena Pharmaceuticals
  • Most Recent Events

    • 12 Jun 2008 Positive results has been presented in an oral presentation at SLEEP 2008 22nd Annual Meeting of the Associated Professional Sleep Societies according to an Arena Pharmaceuticals media release.
    • 07 Sep 2007 Status changed from recruiting to completed.
    • 06 Mar 2007 Status changed from planning to recruiting
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top